Ukrain
WHAT IS UKRAIN?
Source: Cam-Cancer.org
Ukrain is a drug based on the extract of the plant Chelidonium majus L (greater chelandine). It is claimed to be effective against a range of cancers.
History / providers
Ukrain was developed in 1978 by Dr. Wassil J. Nowicky, director of the Ukrainian Anti-Cancer Institute of Vienna, Austria and first presented at the 13th International Congress of Chemotherapy in Vienna in August 1983.
In 2004 and 2006, Nowicky was nominated for the Nobel Prize in Chemistry. The manufacturer of Ukrain is Nowicky Pharma, A-1040 Vienna, Austria.
Ukrain clinical summary
Source: Memorial Sloan Kettering Cancer Center
Brand Name: Ukrain™ (Nowicky Pharma, Vienna, Austria)
Clinical Summary
Ukrain demonstrated antitumor effects in vitro and in animal studies . A systematic review of clinical trials suggests that Ukrain may have potential as an anticancer drug but well designed studies are needed. It may prolong survival in pancreatic cancer patients when administered with gemcitabine but large scale studies are needed to confirm this effect.
Reported adverse effects include injection site reactions, slight fever, fatigue, dizziness, nausea, and possibly tumor bleeding.
“Ukrain is a unique product that acts in at least two ways on cancer (by killing cells and by increasing the immune response).”
Ralph W. Moss, Ph.D.
“Ukrain is capable of improving the general conditions and prolonging the lives of terminal cancer patients by boosting their immune systems and inhibiting tumour growth.”
Douglas Brodie, M.D.
Studies
The Ukrainian Anti Cancer Institute has this on it’s website:
Incredible results of the treatment of pancreatic cancer were achieved during clinical research studies with NSC-631570 (UKRAIN) carried out by Associate Professor Gansauge and Professor Hans Beger in Germany. They showed that 30% of pancreatic cancer patients lived more than 5 years after treatment with NSC 631570, while medical statistics show that after conventional treatment methods patients with the same diagnosis live only 4-6 months and only 2.2% of them reach the 5-year-survival rate.
This study says:
The data obtained in the present studies indicate that Ukrain is responsible for severe changes in morphology of tumour cells. Histological examination by both light and electron microscopy revealed cells characteristic of those undergoing apoptosis. The stromal changes of the tumour were characterized by intensive proliferation of the connective tissue accompanied by an immune reaction expressed by mononuclear infiltrates.
This study concludes:
…our data suggest that Ukrain could be effective as an anticancer drug for breast cancer due to its short-term and long-term inhibitory effects on tumor cell viability and proliferation.
This study concluded: We could show that in unresectable advanced pancreatic cancer, NSC-631570 [ukrain] alone and in combination with gemcitabine nearly doubled the median survival times in patients suffering from advanced pancreatic cancer.
This study, published in the European journal of Cancer states:
In a randomised study 108 patients with advanced colorectal cancer, average 61.2 years, were included. 54 patients were treated with Ukrain as monotherapy and 54 with 5-fluororacil. The therapy results (clinical, haematological, immunological, biochemical) show that Ukrain has favourable properties in the treatment of colorectal cancer and clearly show advantages in contrary to 5-fluorouracil. Stability of the disease was reached in 88.8% and only 27.7% in the control group. The pretreatment with Ukrain facilitated the operability of the patients. The malignotoxic action of Ukrain in the clinic is confirmed by the results of pathomorphosis that gives more possibilities in operative treatment and increases the survival rate. Ukrain is a new effective drug in the therapy of colorectal cancer.
This study says its results suggest that Ukrain can exert some effects on pancreatic tumor progression.
This study says:
In a randomised study 108 patients with advanced colorectal cancer, average 61.2 years, were included. 54 patients were treated with Ukrain as monotherapy and 54 with 5-fluororacil. The therapy results (clinical, haematological, immunological, biochemical) show that Ukrain has favourable properties in the treatment of colorectal cancer and clearly show advantages in contrary to 5-fluorouracil. Stability of the disease was reached in 88.8% and only 27.7% in the control group. The pretreatment with Ukrain facilitated the operability of the patients. The malignotoxic action of Ukrain in the clinic is confirmed by the results of pathomorphosis that gives more possibilities in operative treatment and increases the survival rate. Ukrain is a new effective drug in the therapy of colorectal cancer.
Adverse events
Ukrain is claimed to contain a derivative of thiophosphoric acid, which could cause severe and life-threatening adverse effects.
A literature review of possible cases caused by Chelidonium majus found that it may induce hepatitis and several cases of hepatitis-induced by consumption of Chelidonium majus were found. The researchers suggest there might be a probable relationship between liver injury and consumption of Chelidonium majus.
Where can I get this treatment and more information?
Available Online
See Ukrain.ua
Note: I emailed Dr Nowicky in November 2020 asking how to access Ukrain. He provided the following telephone numbers but no other info:
+3569 966 57 27 or +38 095 721 99 02
10 am – 8 pm GMT+1
German English Ukrainian Russian Polish
See Ukrainian Anti Cancer Institute
Page updated 2024